Compare Fox Corp Class B (FOX) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Organon & Co. Common Stock — how do they compare? Fox Corp Class B trades at $55.56 (market cap $24.91B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Fox Corp Class B is far larger — about 6.9× Organon & Co. Common Stock's market cap, and Fox Corp Class B pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Organon & Co. Common Stock for 0 Days on average.
| FOX | OGN | |
|---|---|---|
Market Cap | $24.91B | $3.62B |
Volume | 395,394 | 2,892,999 |
Sector | Media | Health |
52-Week High | $67.76 | $13.81 |
52-Week Low | $44.39 | $5.70 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $28.27B | $11.04B |
Dividend Yield | 1.04% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.68, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 exceeding the $1.44 estimate. Fundamentals show robust revenue growth to $16.30 billion in 2025 and a net income margin of 13.88%. Analyst consensus is a Buy with a $84.75 price target, implying significant upside, though cash flow projections for 2026 indicate a potential net outflow.
The outlook for FOX is positive based on solid fundamentals and analyst optimism, but risks include a projected net cash flow deficit in 2026 and competitive pressures in the media sector. The stock presents a value opportunity with a P/E of 14.56 trading below the analyst target, yet investors should monitor execution against future earnings expectations and industry headwinds.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
